Belfiglio A, Traietti P, Bologna E, Salvo G
Department of Medicine, Ospedale Fatebenefratelli, Rome, Italy.
Clin Ther. 1989 Jul-Aug;11(4):479-84.
Patients with peripheral obliterative arterial disease received 400 mg of defibrotide intravenously (seven patients) or orally (nine patients). Blood and plasma viscosity were measured before therapy, at 30 minutes after and one hour after intravenous administration, and at 1, 2, 3, and 8 hours after oral administration. Thirty minutes after intravenous administration, blood viscosity at a shear rate of 30 sec-1 was reduced from 9.99 to 9.00 and at a shear rate of 180 sec-1 from 6.61 to 6.33 (P less than 0.05). Viscosity returned to baseline after 60 minutes. At 1, 2, and 3 hours after oral administration, blood viscosity at a shear rate of 30 sec-1 was reduced from 8.53 to 7.44, 6.88, and 7.19 (each P less than 0.01) and at a shear rate of 180 sec-1 from 5.88 to 5.51 (P less than 0.05), 5.14 (P less than 0.05), and 5.38 (P less than 0.01); the levels at eight hours were not significantly different from baseline values. Plasma viscosity was not affected by defibrotide. These data confirm previous evidence of a rheologic effect of defibrotide in patients with peripheral obliterative arterial disease and indicate that such an effect can be achieved with oral administration.
患有外周闭塞性动脉疾病的患者静脉注射（7例患者）或口服（9例患者）400毫克去纤苷。在治疗前、静脉给药后30分钟和1小时以及口服给药后1、2、3和8小时测量血液和血浆粘度。静脉给药后30分钟，剪切速率为30秒-1时的血液粘度从9.99降至9.00，剪切速率为180秒-1时从6.61降至6.33（P小于0.05）。60分钟后粘度恢复到基线水平。口服给药后1、2和3小时，剪切速率为30秒-1时的血液粘度从8.53降至7.44、6.88和7.19（均P小于0.01），剪切速率为180秒-1时从5.88降至5.51（P小于0.05）、5.14（P小于0.05）和5.38（P小于0.01）；8小时时的水平与基线值无显著差异。血浆粘度不受去纤苷影响。这些数据证实了先前关于去纤苷对外周闭塞性动脉疾病患者流变学作用的证据，并表明口服给药可达到这种效果。
